Use of anti-EGFR agents among elderly patients with metastatic colorectal cancer (mCRC).

被引：0
|
作者：
D'Silva, Ashley James
Dotan, Efrat
Kloth, Dwight D.
Beck, Andrew
Cohen, Steven J.
Denlinger, Crystal Shereen
机构：
[1] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA
[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
657
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
    Yang, Jiao
    Li, Shuting
    Wang, Biyuan
    Wu, Yinying
    Chen, Zheling
    Lv, Meng
    Lin, Yayun
    Yang, Jin
    TUMOR BIOLOGY, 2016, 37 (09) : 11645 - 11655
  • [22] Current concepts of anti-EGFR targeting in metastatic colorectal cancer
    Doleschal, Bernhard
    Petzer, Andreas
    Rumpold, Holger
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
    Martins, Marta
    Mansinho, Andre
    Cruz-Duarte, Raquel
    Martins, Soraia Lobo
    Costa, Luis
    TARGETED THERAPY OF COLORECTAL CANCER SUBTYPES, 2018, 1110 : 113 - 131
  • [24] Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
    Pietrantonio, Filippo
    Vernieri, Claudio
    Siravegna, Giulia
    Mennitto, Alessia
    Berenato, Rosa
    Perrone, Federica
    Gloghini, Annunziata
    Tamborini, Elena
    Lonardi, Sara
    Morano, Federica
    Picciani, Benedetta
    Busico, Adele
    Volpi, Chiara Costanza
    Martinetti, Antonia
    Battaglin, Francesca
    Bossi, Ilaria
    Pellegrinelli, Alessio
    Milione, Massimo
    Cremolini, Chiara
    Di Bartolomeo, Maria
    Bardelli, Alberto
    de Braud, Filippo
    CLINICAL CANCER RESEARCH, 2017, 23 (10) : 2414 - 2422
  • [25] Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
    Zlobec, Inti
    Molinari, Francesca
    Martin, Vittoria
    Mazzucchelli, Luca
    Saletti, Piercarlo
    Trezzi, Rosangela
    De Dosso, Sara
    Vlajnic, Tatjana
    Frattini, Milo
    Lugli, Alessandro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (38) : 4823 - 4831
  • [26] Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
    Inti Zlobec
    Francesca Molinari
    Vittoria Martin
    Luca Mazzucchelli
    Piercarlo Saletti
    Rosangela Trezzi
    Sara De Dosso
    Tatjana Vlajnic
    Milo Frattini
    Alessandro Lugli
    World Journal of Gastroenterology, 2010, 16 (38) : 4823 - 4831
  • [27] MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies
    Cappuzzo, Federico
    Sacconi, Andrea
    Landi, Lorenza
    Ludovini, Vienna
    Biagioni, Francesca
    D'Incecco, Armida
    Capodanno, Alessandra
    Salvini, Jessica
    Corgna, Enrichetta
    Cupini, Samanta
    Barbara, Cecilia
    Fontanini, Gabriella
    Crino, Lucio
    Blandino, Giovanni
    CLINICAL COLORECTAL CANCER, 2014, 13 (01) : 37 - U62
  • [28] Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
    Cremolini, Chiara
    Montagut, Clara
    Ronga, Philippe
    Venturini, Filippo
    Yamaguchi, Kensei
    Stintzing, Sebastian
    Sobrero, Alberto
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [29] Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients
    Smith, D.
    Bosacki, C.
    Merrouche, Y.
    BULLETIN DU CANCER, 2009, 96 : S31 - S40
  • [30] Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
    F Di Fiore
    R Sesboüé
    P Michel
    J C Sabourin
    T Frebourg
    British Journal of Cancer, 2010, 103 : 1765 - 1772
12345